In this issue:
HRQoL and pain outcomes with 177Lu-PSMA-617
Metastasis-directed therapy + ADT for oligometastatic prostate cancer
5α-reductase inhibitors and prostate cancer mortality
Niraparib + abiraterone acetate for mCRPC
Dose-escalated radiotherapy + short-term ADT
Biopsy-based genomic classifier in high-risk prostate cancer
Salvage stereotactic reirradiation for local recurrence after prostatectomy
Confocal laser microscopy for surgical margin assessment
AS despite reclassification to Grade Group 2
Treatment of prostate cancer in the US vs England
Please login below to download this issue (PDF)